Patent: 8,563,269

Summary for Patent: 8,563,269

Title:	Modified antibody compositions, methods of making and using thereof
Abstract:	The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Inventor(s):	Stagliano; Nancy E. (Santa Barbara, CA), West; James W. (Santa Barbara, CA), Kamath; Kathryn (Santa Barbara, CA), Bessette; Paul H. (Camarillo, CA), Gluck; Frederick W. (Santa Barbara, CA), Sagert; Jason (Santa Barbara, CA), Daugherty; Patrick (Santa Barbara, CA)
Assignee:	CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:	13/315,623
Patent Claims:	see list of patent claims

Details for Patent 8,563,269

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2029-01-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2029-01-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2029-01-12
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2029-01-12